The NEOLETRIB trial: Neoadjuvant treatment with letrozole and ribociclib in ER-positive, HER2-negative breast cancer

In the NEOLETRIB trial, patients with ER+ HER2- luminal A/B breast cancer were treated with a combination of letrozole and ribociclib in the neoadjuvant setting. By biobanking blood samples and taking tumor biopsies and gut microbiome specimens of patients receiving treatment, the investigators aim to help identify patient populations that could benefit from this combination and thereby reduce the use of traditional neoadjuvant chemotherapy.